Hexestrol

Hexestrol, sold under the brand name Synestrol among others, is a nonsteroidal estrogen which was previously used for estrogen replacement therapy and in the treatment of certain hormone-dependent cancers as well as gynecological disorders but is mostly no longer marketed.[1][2][3][4] It has also been used in the form of esters such as hexestrol diacetate (brand name Sintestrol) and hexestrol dipropionate (brand name Hexanoestrol).[1][5] Hexestrol and its esters are taken by mouth, held under the tongue, or via injection into muscle.[5][6][7]

Hexestrol

Clinical data
Trade names	Synestrol, Synoestrol, Estrifar, Estronal
Other names	Hexoestrol; Hexanestrol; Hexanoestrol; Dihydrodiethylstilbestrol; Dihydrostilbestrol; 4,4'-(1,2-Diethylethylene)diphenol; NSC-9894
Routes of administration	By mouth, intramuscular injection (as an ester)
Drug class	Nonsteroidal estrogen
Identifiers
IUPAC name 4-[4-(4-Hydroxyphenyl)hexan-3-yl]phenol
CAS Number	84-16-2
PubChem CID	3606
IUPHAR/BPS	2823
DrugBank	DB07931
ChemSpider	3480
UNII	10BI795R7D
KEGG	D01641
ChEBI	CHEBI:31669
ChEMBL	ChEMBL6615
CompTox Dashboard (EPA)	DTXSID2022381
ECHA InfoCard	100.001.380
Chemical and physical data
Formula	C18H22O2
Molar mass	270.372 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCC(C1=CC=C(C=C1)O)C(CC)C2=CC=C(C=C2)O
InChI InChI=1S/C18H22O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,17-20H,3-4H2,1-2H3 Key:PBBGSZCBWVPOOL-UHFFFAOYSA-N

Medical uses

Hexestrol has been used in estrogen replacement therapy, for the treatment of breast cancer in women and prostate cancer in men, and for the treatment of certain gynecological disorders.[2]

Estrogen dosages for prostate cancer

Route/form	Estrogen	Dosage
Oral	Estradiol	1–2 mg 3x/day
	Conjugated estrogens	1.25–2.5 mg 3x/day
	Ethinylestradiol	0.15–3 mg/day
	Ethinylestradiol sulfonate	1–2 mg 1x/week
	Diethylstilbestrol	1–3 mg/day
	Dienestrol	5 mg/day
	Hexestrol	5 mg/day
	Fosfestrol	100–480 mg 1–3x/day
	Chlorotrianisene	12–48 mg/day
	Quadrosilan	900 mg/day
	Estramustine phosphate	140–1400 mg/day
Transdermal patch	Estradiol	2–6x 100 μg/day Scrotal: 1x 100 μg/day
IM or SC injection	Estradiol benzoate	1.66 mg 3x/week
	Estradiol dipropionate	5 mg 1x/week
	Estradiol valerate	10–40 mg 1x/1–2 weeks
	Estradiol undecylate	100 mg 1x/4 weeks
	Polyestradiol phosphate	Alone: 160–320 mg 1x/4 weeks With oral EE: 40–80 mg 1x/4 weeks
	Estrone	2–4 mg 2–3x/week
IV injection	Fosfestrol	300–1200 mg 1–7x/week
	Estramustine phosphate	240–450 mg/day
Note: Dosages are not necessarily equivalent. Sources: See template.

Pharmacology

Pharmacodynamics

Hexestrol has approximately 302% and 234% of the affinity of estradiol for the estrogen receptors (ERs) ERα and ERβ, respectively.[8] The affinity of hexestrol for the ERs is said to be similar to or slightly higher than that of estradiol.[9] Along with diethylstilbestrol, hexestrol has been said to be one of the most potent estrogens known.[10] The total endometrial proliferation dose per cycle of different forms of hexestrol are 70 to 100 mg for oral hexestrol, 45 mg for sublingual hexestrol diacetate, and 25 mg for hexestrol dipropionate by intramuscular injection.[5] These doses are fairly similar to those of estradiol and its esters.[5] Hexestrol induces mammary gland development in rodents similarly to other estrogens.[11]

Parenteral potencies and durations of nonsteroidal estrogens

Estrogen	Form	Major brand name(s)	EPD (14 days)	Duration
Diethylstilbestrol (DES)	Oil solution	Metestrol	20 mg	1 mg ≈ 2–3 days; 3 mg ≈ 3 days
Diethylstilbestrol dipropionate	Oil solution	Cyren B	12.5–15 mg	2.5 mg ≈ 5 days
	Aqueous suspension	?	5 mg	? mg = 21–28 days
Dimestrol (DES dimethyl ether)	Oil solution	Depot-Cyren, Depot-Oestromon, Retalon Retard	20–40 mg	?
Fosfestrol (DES diphosphate)^a	Aqueous solution	Honvan	?	<1 day
Dienestrol diacetate	Aqueous suspension	Farmacyrol-Kristallsuspension	50 mg	?
Hexestrol dipropionate	Oil solution	Hormoestrol, Retalon Oleosum	25 mg	?
Hexestrol diphosphate^a	Aqueous solution	Cytostesin, Pharmestrin, Retalon Aquosum	?	Very short
Note: All by intramuscular injection unless otherwise noted. Footnotes: ^a = By intravenous injection. Sources: See template.

Pharmacokinetics

Distribution of hexestrol radioactivity in blood and tissues after a subcutaneous injection of a physiological dose of tritium-labeled hexestrol in oil solution in five juvenile female goats.[12] Points are one animal each.[12] With the exception of skeletal muscle, tissues with a radioactivity concentration of less than 15% of that of the endometrium are not shown.[12] Hexestrol is concentrated in target tissues such as the uterus and vagina due to binding to estrogen receptors.[13]

The pharmacokinetics and distribution of hexestrol have been studied with intravenous injection of aqueous solution in women and with subcutaneous injection of oil solution in female goats and sheep.[14][12]

Chemistry

Hexestrol, also known as dihydrodiethylstilbestrol, is a synthetic nonsteroidal estrogen of the stilbestrol group related to diethylstilbestrol.[1][2] Esters of hexestrol include hexestrol diacetate, hexestrol dicaprylate, hexestrol diphosphate, and hexestrol dipropionate.[1]

History

Hexestrol was first described by Campbell, Dodds, and Lawson in 1938.[15][11][16][17] It was isolated from the demethylation products of anethole.[15][11][16][17]

Society and culture

Generic names

Hexestrol is the generic name of the drug and its INN.[1][2]

Brand names

Hexestrol has been marketed under a variety of brand names including Synestrol, Synoestrol, Estrifar, and Estronal, among others.[1][2]

Availability

Hexestrol has mostly been discontinued and remains available in only a handful of countries.[18][4] Esters of hexestrol which have been marketed include hexestrol diacetate, hexestrol dicaprylate, hexestrol diphosphate, and hexestrol dipropionate.[1]

References

1. J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 162–. ISBN 978-1-4757-2085-3.
2. I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 140–. ISBN 978-94-011-4439-1.
3. John A. Thomas (12 March 1997). Endocrine Toxicology, Second Edition. CRC Press. pp. 144–. ISBN 978-1-4398-1048-4.
4. https://www.drugs.com/international/hexestrol.html
5. J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 83, 85, 145, 310. ISBN 978-94-009-8195-9.
6. John A. Thomas; Edward J. Keenan (6 December 2012). Principles of Endocrine Pharmacology. Springer Science & Business Media. pp. 153–. ISBN 978-1-4684-5036-1.
7. Barar F.S.K. (2012). Textbook of Pharmacology. S. Chand Publishing. pp. 348–. ISBN 978-81-219-4080-1.
8. Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA (1997). "Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta". Endocrinology. 138 (3): 863–70. doi:10.1210/endo.138.3.4979. PMID 9048584.
9. Leclercq G, Heuson JC (December 1979). "Physiological and pharmacological effects of estrogens in breast cancer". Biochim. Biophys. Acta. 560 (4): 427–55. doi:10.1016/0304-419x(79)90012-x. PMID 391285.
10. SOLMSSEN UV (1945). "Synthetic estrogens and the relation between their structure and their activity". Chem. Rev. 37 (3): 481–598. doi:10.1021/cr60118a004. PMID 21013428.
11. Campbell, N.R.; Dodds, E.C.; Lawson, W.; Noble, R.L. (1939). "Biological effects of the synthetic œstrogen hexœstrol". The Lancet. 234 (6049): 312–313. doi:10.1016/S0140-6736(00)61997-9. ISSN 0140-6736.
12. Glascock RF, Hoekstra WG (August 1959). "Selective accumulation of tritium-labelled hexoestrol by the reproductive organs of immature female goats and sheep". Biochem. J. 72 (4): 673–82. doi:10.1042/bj0720673. PMC 1196992. PMID 13828338.
13. Jensen EV, DeSombre ER (1972). "Mechanism of action of the female sex hormones". Annu. Rev. Biochem. 41: 203–30. doi:10.1146/annurev.bi.41.070172.001223. PMID 4563437.
14. Folca PJ, Glascock RF, Irvine WT (October 1961). "Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy". Lancet. 2 (7206): 796–8. doi:10.1016/s0140-6736(61)91088-1. PMID 13893792.
15. Campbell, N. R.; Dodds, E. C.; Lawson, W. (1938). "Œstrogenic Activity of Anol; a Highly Active Phenol Isolated from the By-Products". Nature. 142 (3608): 1121. doi:10.1038/1421121a0. ISSN 0028-0836. S2CID 4140616.
16. Medicinal Chemistry. John Wiley & Sons. 1956. p. 40.
17. Campbell NR, Dodds EC, Lawson W (1940). "The nature of the oestrogenic substances produced during the demethylation of anethole". Proceedings of the Royal Society of London. Series B - Biological Sciences. 128 (851): 253–262. doi:10.1098/rspb.1940.0009. ISSN 2053-9193.
18. https://www.micromedexsolutions.com/